In vitro and in vivo studies on plasma-to-blood ratio of paclitaxel in human, rabbit and rat blood fractions.

Many pharmacokinetic studies of paclitaxel formulations with or without Cremophor (CrEL) have been performed on experimental animals. However, limited studies describe the different pharmacokinetic behaviors of paclitaxel in animals. The different distribution of drug in blood fractions may have great effect on its pharmacokinetic behaviors. Our present study was designed to study the characteristics of paclitaxel distribution in human, rabbit and rat blood, by measuring plasma-to-blood ratio (PBR) of paclitaxel in vitro and in vivo, and analyzing the results of equilibrium dialysis of paclitaxel with erythrocyte, plasma and hemoglobin. It was demonstrated that the paclitaxel PBR values in rat, unlike those in rabbit, are most significantly different from those in human, which may be due to distinct affinity of paclitaxel to blood fractions among different species. The effect of CrEL on increasing paclitaxel plasma concentration and in vitro & in vivo correlation in animal PBR values were observed. The findings in this study are of significance in the evaluation of the newly developed formulations of paclitaxel.

[1]  Q. Guo,et al.  Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. , 2008, Biomaterials.

[2]  K. P. Madhusudanan,et al.  In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey—highlighting species similarities and differences , 2007, Biopharmaceutics & drug disposition.

[3]  M. Highley,et al.  In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender , 2005, Anti-cancer drugs.

[4]  M. Highley,et al.  In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking , 2005, Anti-cancer drugs.

[5]  Michael Hawkins,et al.  Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) , 2005, Clinical Cancer Research.

[6]  J. Zhang,et al.  Lyophilized Paclitaxel Magnetoliposomes as a Potential Drug Delivery System for Breast Carcinoma via Parenteral Administration: In Vitro and in Vivo Studies , 2005, Pharmaceutical Research.

[7]  K. Miyamoto,et al.  Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles , 2004, The Journal of pharmacy and pharmacology.

[8]  Alex Sparreboom,et al.  Role of Formulation Vehicles in Taxane Pharmacology , 2001, Investigational New Drugs.

[9]  J. Verweij,et al.  Pharmacological Effects of Formulation Vehicles , 2003, Clinical pharmacokinetics.

[10]  D. Schrijvers.  Role of Red Blood Cells in Pharmacokinetics of Chemotherapeutic Agents , 2003, Clinical pharmacokinetics.

[11]  A. Wolff,et al.  Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[13]  J. Verweij,et al.  Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Highley,et al.  Erythrocytes and the transfer of anticancer drugs and metabolites: a possible relationship with therapeutic outcome. , 2001, Seminars in oncology.

[15]  J. Verweij,et al.  Measurement of fraction unbound paclitaxel in human plasma. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[16]  F. Dosio,et al.  Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[17]  J Verweij,et al.  Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.

[18]  J. Verweij,et al.  Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[19]  J. Verweij,et al.  Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. , 1998, Analytical biochemistry.

[20]  D. Morgan,et al.  Effect of erythrocyte binding on elimination of harmol by the isolated perfused rat liver. , 1996, Journal of pharmaceutical sciences.

[21]  Gotaskie Ge,et al.  Paclitaxel: a new antimitotic chemotherapeutic agent. , 1994 .

[22]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[23]  C. Goresky,et al.  Red Cell Carriage of Label: ITS LIMITING EFFECT ON THE EXCHANGE OF MATERIALS IN THE LIVER , 1975, Circulation research.